TP53 and prostate carcinoma: For example, using such a model, Elmarakeby et al. found that metastatic outcomes in prostate cancer were well predicted by convergent genetic alterations within a mouse double minute (MDM)–tumor protein 53 (TP53) inhibition pathway, implicating MDM4 in resistance to antiandrogen therapy15.